Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Neoplasms: early-phase trial registry
16 of 39 indexed Ovarian Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #382 of 28,707 conditions by registered trial count.
39 US clinical trials · 16 currently recruiting · #382 of 28,707 conditions by registered trial count
Ovarian Neoplasms: 39 US clinical trials tracked, 16 recruiting.
Ovarian Neoplasms is the subject of 39 registered US clinical trials on ClinicalTrials.gov, 16 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 5 of these trials.
Enrollment posture brief
Registry condition ovarian-neoplasms
OPEN 16 | RECR 41% | LATE 7 | EARLY 23 | RANK #382 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Renal Cell Carcinoma (41% recruiting · 122 trials)
Ovarian Neoplasms lists 16 open slots (41% of 39 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Neoplasms recruits in line with its size-band peers.
16 of 39 indexed trials (41%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Ovarian Neoplasms trials is spread across many organizations.
Eli Lilly and Company accounts for 5 of 39 trials (12.8%). 30 distinct sponsors appear on at least one study for this condition label.
-
Typical Ovarian Neoplasms enrolment sits around 160 participants.
Median target enrolment is 160 among the 39 trials that report a genuine target (sentinel values excluded). 12 of those (30.8%) plan for fewer than 100 participants.
-
Ovarian Neoplasms research is mostly interventional.
33 interventional and 6 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
39 total, page 1 of 1
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Eli Lilly and Company
NCT07213804
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass
Cleo Diagnostics
NCT06566716
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Merck Sharp & Dohme
NCT07318558
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
NCT04956640
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
NCT06400472
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
Massachusetts General Hospital
NCT04794322
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
NCT07213791
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
A Study of DM002 in Patients With Advanced Solid Tumors
Xadcera Biopharmaceutical (Suzhou) Co.
NCT06751329
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT06586957
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Dana-Farber Cancer Institute
NCT06543537
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06885697
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
Mayo Clinic
NCT07280312
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
NCT04641247
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Tesaro
NCT03602859
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
NCT00579163
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Tesaro
NCT02655016
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
CanariaBio
NCT04498117
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen, a wholly owned subsidiary of Pfizer
NCT06003231
A Trial of Vigil for Participants With Ovarian Cancer
Gradalis
NCT02346747
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT06466187
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
National Cancer Institute (NCI)
NCT05185947
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences
NCT05617755
Biobehavioral-Cytokine Interactions in Ovarian Cancer
Susan Lutgendorf
NCT01113112
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Janssen Research & Development
NCT01846611
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
Tesaro
NCT02354586
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Bayer
NCT00791778
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
Eli Lilly and Company
NCT00191607
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas
Pierian Biosciences
NCT00443196
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
University of Michigan
NCT02444195
Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma
NYU Langone Health
NCT00531570
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech
NCT01616303
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
Translational Research in Oncology
NCT00719212
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Novartis Pharmaceuticals
NCT00035100
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics
NCT00120939
Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients
Gynecologic Oncology Associates
NCT00127920
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
Sanofi
NCT00396591
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 12 |
| Phase 3 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Neoplasms page
39 registered trials, 16 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 16 Ovarian Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Ovarian Neoplasms trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Neoplasms condition card totals 39 registered trials; most-linked intervention Niraparib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.